Previous 10 | Next 10 |
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2019 Q2 earnings Read more ...
Horizon Pharma ( HZNP ) Q2 results : Revenues: $320.6M (+5.9%); Orphan and Rheumatology Sales: $223.5M (+10.8%). More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Horizon Pharma (NASDAQ: HZNP ): Q2 Non-GAAP EPS of $0.49 beats by $0.12 ; GAAP EPS of -$0.03. More news on: Horizon Therapeutics Public Limited Company, Earnings news and commentary, Healthcare stocks news, Read more ...
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million; KRYSTEXXA ® Second-Quar...
AMAG , ANIP , ATHM , ATKR , AVA , BCOR , BV , CNP , CORE , CPRI , CSTE , CVS , CYBR , DNR , DOC , ETM , EVOP , FUN , GOLF , GTN , HL , HZNP , ICPT , INGN , INXN , IONS , JELD , KELYA , LAMR , LL , LXP , MFA , MIDD , NRG , NVMI , NXST , NYT , ODP , OMI ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the availability of an expanded access program for its investigational medicine teprotumumab. Developed in partnership with the U.S. Food and Drug Administration (FDA), the expanded access program may provide access to teprotumumab for p...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has appointed Dr. Sue Mahony to its board of directors. Dr. Mahony brings more than three decades of broad cross-functional and global experience to the board. Most recently, she served as senior vice president of Eli Lilly a...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the company has won a Gold International CSR Excellence Award in the Large Business category for its partnership with Chicago-based school, Perspectives Math and Science Academy (MSA). A video highlighting the partnership can be fou...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets. If approved by the FDA, this new dosage form w...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug. 7, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...